Education
About Us
Working with TipRanks
Follow Us
Disc Medicine (IRON)
NASDAQ:IRON
IRON Stock Chart & Stats
$80.01
$0.74(1.19%)
At close: 4:00 PM EST
$80.01
$0.74(1.19%)
Day’s Range― - ―
52-Week Range$30.82 - $99.50
Previous CloseN/A
Volume41.94K
Average Volume (3M)592.40K
Market Cap
$3.10B
Enterprise Value$2.86B
Total Cash (Recent Filing)$615.92M
Total Debt (Recent Filing)$30.98M
Price to Earnings (P/E)―
Beta1.74
Next Earnings
Mar 27, 2026EPS Estimate
-1.75Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.77
Shares Outstanding37,750,160
10 Day Avg. Volume621,806
30 Day Avg. Volume592,403
Financial Highlights & Ratios
PEG Ratio-1.01
Price to Book (P/B)3.95
Price to Sales (P/S)0.00
P/FCF Ratio-18.53
Enterprise Value/Market Cap0.92
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-29.75K
Enterprise Value/Ebitda-17.66
Forecast
1Y Price Target
$123.44Price Target Upside54.28% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)-6.72
Revenue Forecast (FY)$47.41M
Bulls Say, Bears Say
Bulls Say
Commercial ReadinessCompany has built commercial infrastructure by hiring rare disease sales specialists, medical science liaisons, and field access staff to support patient starts at priority accounts, improving launch preparedness if approved.
Regulatory EngagementManagement reports productive, continuous interactions with the agency and analysts' base case expects approval via the Commissioner's priority voucher review process, implying regulatory momentum remains intact.
Surrogate Endpoint SupportManagement and analysts emphasize that consistent reductions in PPIX are an accepted surrogate endpoint and that agency agreement on this biomarker strengthens the case for accelerated approval of bitopertin.
Bears Say
Clinical Endpoint RiskThe main trial's pain-free time in sunlight endpoint was not statistically significant, which could complicate a case for full approval and prompt requests for additional evidence.
Media-driven Market ImpactUnconfirmed media reports raising efficacy and abuse concerns triggered a pronounced share selloff, demonstrating that negative coverage can quickly amplify perceived approval risk.
Regulatory Timeline UncertaintyGreater reliance on expedited review pathways combined with staffing constraints at the agency increases the risk of review delays and creates uncertainty around timing under the priority voucher program.
Disc Medicine News
IRON FAQ
What was Disc Medicine’s price range in the past 12 months?
Disc Medicine lowest stock price was $30.82 and its highest was $99.50 in the past 12 months.
What is Disc Medicine’s market cap?
Disc Medicine’s market cap is $3.10B.
When is Disc Medicine’s upcoming earnings report date?
Disc Medicine’s upcoming earnings report date is Mar 27, 2026 which is in 56 days.
How were Disc Medicine’s earnings last quarter?
Disc Medicine released its earnings results on Nov 06, 2025. The company reported -$1.77 earnings per share for the quarter, missing the consensus estimate of -$1.442 by -$0.328.
Is Disc Medicine overvalued?
According to Wall Street analysts Disc Medicine’s price is currently Undervalued.
Does Disc Medicine pay dividends?
Disc Medicine does not currently pay dividends.
What is Disc Medicine’s EPS estimate?
Disc Medicine’s EPS estimate is -1.75.
How many shares outstanding does Disc Medicine have?
Disc Medicine has 37,750,160 shares outstanding.
What happened to Disc Medicine’s price movement after its last earnings report?
Disc Medicine reported an EPS of -$1.77 in its last earnings report, missing expectations of -$1.442. Following the earnings report the stock price went down -1.483%.
Which hedge fund is a major shareholder of Disc Medicine?
Currently, no hedge funds are holding shares in IRON
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Disc Medicine Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$123.44 (54.28% Upside)
$123.44 (54.28% Upside)
Blogger Sentiment
Bullish
IRON Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth $16.9M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.8%
Last 30 Days ▲ 6.0%
Last 30 Days ▲ 6.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
46.78%
12-Months-Change
Fundamentals
Return on Equity
-34.78%
Trailing 12-Months
Asset Growth
27.33%
Trailing 12-Months
Company Description
Disc Medicine
Disc Medicine, Inc., a clinical-stage biotechnology company, engages in discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. It builds a portfolio of therapeutic candidates that address a spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology, primarily heme biosynthesis and iron homeostasis. The company is based in Watertown, Massachusetts.
IRON Stock 12 Month Forecast
Average Price Target
$123.44
▲(54.28% Upside)
Technical Analysis
Agios Pharma
―
Travere Therapeutics
―
Arcutis Biotherapeutics
―
Tarsus Pharmaceuticals
―
Recursion Pharmaceuticals
―
Ownership Overview
9.74% Insiders
23.27% Mutual Funds
0.95% Other Institutional Investors
56.04% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---